|
Obesity
|
0.520 |
Biomarker
|
disease |
RGD |
SD rat fed with a HF diet showed different susceptibility to obesity, and up-regulated hypothalamic NPY and Y1, Y2, Y5 receptor gene expressions were closely associated with being predisposed to obesity and overeating of DIO rats.
|
17447163 |
2007 |
|
Obesity
|
0.520 |
Biomarker
|
disease |
CTD_human |
Novel polymorphisms in the neuropeptide-Y Y5 receptor associated with obesity in Pima Indians.
|
10849579 |
2000 |
|
Obesity
|
0.520 |
Biomarker
|
disease |
BEFREE |
NPY deficiency attenuates the obesity syndrome of mice deficient for leptin (ob/ob), but these effects are not mediated by NPY signaling through the Y5R because Y5R-null ob/ob mice are equally obese.
|
9623983 |
1998 |
|
Obesity
|
0.520 |
Biomarker
|
disease |
BEFREE |
Our data support the idea that the Y5 receptor is the postulated 'feeding' receptor, and may provide a new method for the study and treatment of obesity and eating disorders.
|
8700207 |
1996 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Several lines of evidence in both human and animal studies suggest that variation in neuropeptide Y (NPY) or its receptor genes (NPY1R, NPY2R and NPY5R) is associated with alcohol dependence as well as alcohol withdrawal symptoms.
|
18828811 |
2008 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
BEFREE |
Several lines of evidence in both human and animal studies suggest that variation in neuropeptide Y (NPY) or its receptor genes (NPY1R, NPY2R and NPY5R) is associated with alcohol dependence as well as alcohol withdrawal symptoms.
|
18828811 |
2008 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
PSYGENET |
The purpose of this study was to determine if NPY Y5 receptor antagonism reduces ethanol self-administration and reinforcement in a rodent genetic animal model of alcoholism.
|
16377459 |
2005 |
|
Alcohol abuse
|
0.300 |
Biomarker
|
disease |
PSYGENET |
For this reason, NPY Y5 receptor antagonists may be useful in medical management of alcohol abuse and alcoholism in the human population.
|
16377459 |
2005 |
|
Absence Epilepsy
|
0.200 |
Therapeutic
|
disease |
RGD |
Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
|
17331209 |
2007 |
|
Hyperinsulinism
|
0.200 |
Biomarker
|
disease |
RGD |
Our data suggest that selective activation of central NPY Y1 receptor subtype induced hyperinsulinemia independent of food ingestion, whereas the NPY Y5 receptor-induced hyperinsulinemia was dependent on food ingestion.
|
15187000 |
2004 |
|
Coronary Restenosis
|
0.200 |
Biomarker
|
disease |
RGD |
Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery.
|
12689918 |
2003 |
|
Inflammation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26).
|
12161018 |
2002 |
|
Leukocytosis
|
0.200 |
Biomarker
|
phenotype |
RGD |
NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization.
|
12417430 |
2002 |
|
Prolactinoma
|
0.200 |
Biomarker
|
disease |
RGD |
Upregulation of pancreatic polypeptide-sensitive neuropeptide Y (NPY) receptors in estrogen-induced hypertrophy of the anterior pituitary gland in the Fischer-344 rat.
|
11026575 |
2000 |
|
Visual seizure
|
0.200 |
Biomarker
|
disease |
RGD |
Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors.
|
9212103 |
1997 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our previous studies have identified neuropeptide Y (NPY), a sympathetic neurotransmitter expressed in NB, as a potential therapeutic target for these tumors by virtue of its Y5 receptor (Y5R)-mediated chemoresistance and Y2 receptor (Y2R)-mediated proliferative and angiogenic activities.
|
27743558 |
2016 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
|
25132261 |
2015 |
|
Panic Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Among previous candidate genes, supportive evidence for association of NPY5R with PD was obtained (gene-wise corrected P=6.4 × 10(-4)).
|
23149450 |
2012 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
NPY5R was found to be associated with dyslipidemia using the Genetic Association Database.
|
20797317 |
2010 |
|
Panic Disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The present results provide preliminary support for an influence of NPY Y5 receptor variants on the etiology of panic disorder in a potentially gender-specific manner further strengthening the evidence for a risk locus on chromosome 4q31-q34 in anxiety disorders.
|
17948870 |
2008 |
|
Dyslipidemias
|
0.020 |
GeneticVariation
|
group |
LHGDN |
These preliminary results provide evidence for association of SNPs in the NPY5R gene with dyslipidemia (elevated triglyceride concentrations and reduced high-density lipoprotein levels) in our Mexican American population.
|
17426313 |
2007 |
|
Dyslipidemias
|
0.020 |
GeneticVariation
|
group |
BEFREE |
These preliminary results provide evidence for association of SNPs in the NPY5R gene with dyslipidemia (elevated triglyceride concentrations and reduced high-density lipoprotein levels) in our Mexican American population.
|
17426313 |
2007 |
|
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
|
25132261 |
2015 |
|
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
|
25132261 |
2015 |
|
Chronic myeloproliferative disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal expression of several STAT5-p53 target genes (LEP, ATP5J, GTF2A2, VEGFC, NPY1R and NPY5R) is frequently detected in platelets of myeloproliferative neoplasm (MPN) patients, but not in platelets from healthy controls.
|
24681953 |
2015 |